We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6141:TSEDMG MORI CO., LTD. Analysis

Data as of 2026-03-15 - not real-time

NT$20.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Plotech Co.,Ltd is riding a strong technical wave, with the 20‑day SMA (≈14.14) comfortably above the 50‑day (≈12.45) and 200‑day (≈12.20) averages, and a bullish MACD histogram supporting further upside. However, the RSI is perched at 83, signaling that the stock is deeply overbought and may be vulnerable to a short‑term pull‑back. Volume is on an increasing trend, reinforcing the current momentum, while the 30‑day volatility is unusually high at over 70%, indicating large price swings. Fundamentally, the picture is stark: revenue is down 17%, margins are negative across the board, and free cash flow is a sizable -$631 M, with a debt‑to‑equity ratio soaring above 270. The DCF fair‑value estimate of roughly 12.65 TWD is far below the current market price of 20 TWD, suggesting the stock is priced well above intrinsic expectations. Yet the forward P/E of 7.84 is dramatically lower than the industry average of 33.7, hinting at a valuation discount if earnings recover. The company carries no dividend, eliminating any income cushion for investors. Geopolitical exposure to Taiwan and China adds a medium‑level geographic risk, while the low beta (≈0.41) tempers market‑wide systematic risk. Overall, the stock sits at the intersection of strong technical signs and severe fundamental weaknesses, making the near‑term outlook uncertain and the longer‑term case dependent on a turnaround in cash generation and debt reduction.
Given the overbought technical condition, high volatility, and deteriorating financial health, the immediate recommendation leans toward caution. The market price remains near the 20‑day resistance level, and without a clear catalyst to improve cash flow or reduce leverage, a pull‑back appears plausible. Investors should monitor earnings releases and any strategic restructuring moves, as these will be pivotal in determining whether the stock can bridge the gap between its lofty price and distressed fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA crossover and MACD signal
  • RSI overbought condition indicating potential pull‑back
  • Weak earnings and high debt burden

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Current price well above DCF fair value
  • Negative free cash flow and deteriorating margins
  • Elevated leverage with debt‑to‑equity > 270

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Forward P/E discount relative to industry peers
  • Potential upside if operational turnaround occurs
  • Continued high volatility and financial fragility

Key Metrics & Analysis

Financial Health

Revenue Growth-16.90%
Profit Margin-25.37%
P/E Ratio7.8
ROE-44.63%
ROA-3.08%
Debt/Equity270.24
P/B Ratio2.2
Op. Cash FlowNT$436.9M
Free Cash FlowNT$-631785280
Industry P/E33.7

Technical Analysis

TrendBullish
RSI83.5
SupportNT$10.50
ResistanceNT$20.00
MA 20NT$14.14
MA 50NT$12.45
MA 200NT$12.20
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueNT$12.65
GradeOvervalued
TypeValue

Risk Assessment

Beta0.73
Volatility71.43%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.